These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 25516724)

  • 1. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
    Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
    Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration.
    Schierbeck H; Pullerits R; Pruunsild C; Fischer M; Holzinger D; Laestadius Å; Sundberg E; Harris HE
    J Rheumatol; 2013 Sep; 40(9):1604-13. PubMed ID: 23858044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
    Myles A; Viswanath V; Singh YP; Aggarwal A
    J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.
    el-Gamal YM; Heshmat NM; el-Kerdany TH; Fawzy AF
    Pediatr Allergy Immunol; 2004 Jun; 15(3):270-7. PubMed ID: 15209962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
    Urbonaviciute V; Voll RE
    J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus.
    Ma CY; Ma JL; Jiao YL; Li JF; Wang LC; Yang QR; You L; Cui B; Chen ZJ; Zhao YR
    Scand J Immunol; 2012 Jun; 75(6):614-22. PubMed ID: 22324318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options?
    Kanakoudi-Tsakalidou F; Farmaki E; Tzimouli V; Taparkou A; Paterakis G; Trachana M; Pratsidou-Gertsi P; Nalbanti P; Papachristou F
    Lupus; 2014 Mar; 23(3):305-12. PubMed ID: 24399813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.
    Yu SL; Wong CK; Szeto CC; Li EK; Cai Z; Tam LS
    Lupus; 2015 Jun; 24(7):675-86. PubMed ID: 25411258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
    Pullerits R; Bokarewa M; Dahlberg L; Tarkowski A
    Arthritis Res Ther; 2005; 7(4):R817-24. PubMed ID: 15987483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Complement-activating Pattern Recognition Molecules and Associated Enzymes as Possible Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis.
    Petri C; Thiel S; Jensenius JC; Herlin T
    J Rheumatol; 2015 Jul; 42(7):1252-8. PubMed ID: 26034144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High mobility group box protein 1-A prognostic marker for structural joint damage in 10-year follow-up of patients with juvenile idiopathic arthritis.
    Pullerits R; Schierbeck H; Uibo K; Liivamägi H; Tarraste S; Talvik T; Sundberg E; Pruunsild C
    Semin Arthritis Rheum; 2017 Feb; 46(4):444-450. PubMed ID: 27756498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis.
    Zicari AM; Zicari A; Nebbioso M; Mari E; Celani C; Lollobrigida V; Cesoni Marcelli A; Occasi F; Duse M
    Pediatr Allergy Immunol; 2014 Feb; 25(1):57-63. PubMed ID: 24236762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.
    Peake NJ; Khawaja K; Myers A; Jones D; Cawston TE; Rowan AD; Foster HE
    Rheumatology (Oxford); 2005 Nov; 44(11):1383-9. PubMed ID: 16049050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
    Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
    Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response.
    Lu M; Yu S; Xu W; Gao B; Xiong S
    J Immunol Res; 2015; 2015():946748. PubMed ID: 26078984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring serum levels of high-mobility group box 1 by enzyme-linked immunosorbent assay does not identify bacterial infections in patients with systemic lupus erythematosus.
    Tang KT; Hsieh TY; Chen YM; Hsieh CW; Chen YH; Chen DY
    Lupus; 2014 Aug; 23(9):926-34. PubMed ID: 24704776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the Inflammatory Properties of Actively Released HMGB1 in Juvenile Idiopathic Arthritis.
    Lundbäck P; Stridh P; Klevenvall L; Jenkins RE; Fischer M; Sundberg E; Andersson U; Antoine DJ; Harris HE
    Antioxid Redox Signal; 2016 Apr; 24(12):605-19. PubMed ID: 25532033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between high mobility group box 1 protein and juvenile idiopathic arthritis: a prospective longitudinal study.
    Xu D; Zhang Y; Zhang ZY; Tang XM
    Pediatr Rheumatol Online J; 2021 Jul; 19(1):112. PubMed ID: 34247641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus.
    Yu SL; Wong CK; Tam LS
    Expert Rev Clin Immunol; 2013 Aug; 9(8):739-49. PubMed ID: 23971752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.